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ABSTRACT. Structural and computational studies to explore the WAT1 binding pocket in the structure-based 
design of inhibitors against the type II dehydroquinase (DHQ2) enzyme are reported. The crystal structures of 
DHQ2 from M. tuberculosis in complex with four of the reported compounds are described. The electrostatic 
interaction observed between the guanidinium group of the essential arginine and the carboxylate group of one 
of the inhibitors in the reported crystal structures supports the recently suggested role of this arginine as the 
residue that triggers the release of the product from the active site. The results of the structural and molecular 
dynamics simulation studies revealed that the inhibitory potency is favored by promoting interactions with 
WAT1 and the residues located within this pocket and, more importantly, by avoiding situations where the 
ligands occupy the WAT1 binding pocket. The new insights can be used to advantage in the structure-based 
design of inhibitors. 
INTRODUCTION 
The increasing development and spread of resistance to current antibiotics has made infectious diseases the 
second most common cause of death worldwide.
1 
Despite this alarming trend, only two new classes of 
antibiotics have been brought to the market in the last three decades and there are only a few antibacterial 
agents under development to face the challenge of multidrug resistance.
2-5 
Hence, there is a great deal of interest 
in the development of alternative therapies, including new strategies for the treatment of infections that are 
resistant to current antibiotics, in particular drugs with new mechanisms of action to combat the growth of 
antibiotic-resistant bacteria.
6
 One strategy to combat bacterial infections is based on the disruption of the growth 
cycle by preventing the synthesis and assembly of key components of bacterial processes.
7-8 
Many drugs that are 
highly successful in human clinical use are mimetics of the substrate or intermediates of key enzymatic 
reactions. For instance, sulfonamide-based drugs are analogs of p-aminobenzoate, the natural substrate of 
dihydropteroate synthase, an essential enzyme in the folic acid biosynthesis pathway. During the past few years, 
a great deal of effort has been focused on the inhibition of the enzymes involved in the shikimic acid pathway, 
in which chorismic acid is synthesized. These enzymes are recognized to be attractive targets for the 




 Special attention has been paid to the inhibition of the third enzyme of the pathway, 
namely type II dehydroquinase (3-dehydroquinate dehydratase, EC 4.2.1.10, DHQ2), which is one of the two 
known DHQ enzymes. DHQ2 is essential in Mycobacterium tuberculosis (aroD gene, Mt-DHQ2),
10
 which is 
responsible for causing tuberculosis, and Helicobacter pylori (aroD/aroQ gene, Hp-DHQ2),
10
 which is the 
causative agent of gastric and duodenal ulcers and has been classified as a type I carcinogen. 
DHQ2 catalyzes the reversible dehydration of 3-dehydroquinic acid (1) to form 3-dehydroshikimic acid (2). The 
anti elimination of water involves the loss of the more acidic pro-S hydrogen from C2 of 1 (Scheme 1).
 
After 
substrate binding, a flexible loop forms a lid that closes the active site. Three residues, an arginine 
(Arg17/Arg19 in Hp-DHQ2 and Mt-DHQ2, respectively), a tyrosine (Tyr22/Tyr24 in Hp-DHQ2 and Mt-DHQ2, 
respectively) and an aspartate (Asp89*/Asp88* in Hp-DHQ2 and Mt-DHQ2, respectively) from the neighboring 
enzyme subunit (residues from this subunit will be marked with an asterisk), were identified by chemical 
modification and site-directed mutagenesis studies as essential for enzyme activity.
11-13
 The elimination 
proceeds by a stepwise E1CB mechanism that involves an enolate intermediate 3.
14,13
 The reaction is initiated by 
the essential Asp89*/Asp88* (Figure 1A). This residue deprotonates the essential Tyr22/Tyr24, which is 
located in the loop, to afford the catalytic tyrosinate, which in turn triggers the enzymatic process.
13
 For the Hp-
DHQ2 enzyme, this reaction takes place with the assistance of a water molecule, while for Mt-DHQ2, the 
tyrosine is directly deprotonated by the aspartate residue.
13
 The guanidinium group of Arg17/Arg19 must be 
close to the essential tyrosine side chain for catalysis because, in this arrangement, it controls the appropriate 
orientation of the tyrosine, which is roughly perpendicular to the cyclohexane ring of the natural substrate, 
through a cation- interaction and contributes to decreasing the pKa of the phenol group.
15 
The tyrosinate 
removes the axial hydrogen from C2 of 1 to give an enolate intermediate 3 (Figure 1B), which is stabilized by 
the positively charged side chain of the essential Arg17/Arg19 and by a hydrogen bond between the neutral 
aspartate Asp89*/Asp88* and a conserved water molecule (henceforth WAT1). The final step is the acid-
catalyzed elimination of the C1 hydroxyl group ‒ a reaction mediated by the conserved histidine His102/His101 
(in Hp-DHQ2 and Mt-DHQ2, respectively) acting as a proton donor.  
 4 
The presence of WAT1 in many crystal structures and its role in the enzymatic mechanism has been widely 
discussed. This water molecule interacts through hydrogen bonding with a conserved asparagine (Asn10/Asn12 
in Hp-DHQ2and Mt-DHQ2, respectively), the carbonyl group of a conserved proline (Pro9/Pro11 in Hp-DHQ2 
and Mt-DHQ2, respectively), and the main-chain amide of a glycine or an alanine (Ala79/Gly78 in Hp-DHQ2 
and Mt-DHQ2, respectively). Initially, it was proposed that this water molecule would be involved in the 
protonation of the enolate intermediate 3 assuming that the side chain of a conserved asparagine (Asn10/Asn12 
in Hp-DHQ2 and Mt-DHQ2, respectively) would be deprotonated by WAT1.
16
 However, considering the high 
energy required to deprotonate the side chain of an asparagine and on the basis of results from quantum 
mechanical (QM) calculations, this possibility was then discarded.
17
 Recently, the results from computational 
studies of the catalytic mechanism (Hp-DHQ2 and Mt-DHQ2) in atomic detail by means of a hybrid QM/MM 
approach suggested that WAT1 would be mainly involved in the stabilization of the substrate and enol 
intermediate 3.
17,13
 Furthermore, the crystal structure of Mt-DHQ2 in complex with a nanomolar reversible 
competitive inhibitor, compound 4c, solved at 1.5 Å shows that the oxygen atom of the methylenoxy spacer of 
4c is located 3.1 Å away from WAT1 (Figure 2).
18
 The aromatic moiety of these compounds blocks the entry of 
the essential arginine side chain into the active site and causes a significant change in the conformation and 
flexibility of the loop, which is essential for the enzymatic activity. Considering that the replacement of the 
oxygen atom of the methylenoxy spacer of 4 by a carbon atom (ethylene spacer) leads to a decrease in the 
inhibition potency of up to 20-fold and that both spacers provides the necessary conformational flexibility to the 
aryl moiety to accommodate in the active site in an extended conformation,
19
 we assume that an important 





DHQ2 and Hp-DHQ2, respectively, is due to the interaction between the oxygen atom of the methylenoxy 
spacer with WAT1.  
Structural water molecules in enzyme active sites are of interest to medicinal chemists because they can 
increase the binding affinity of a ligand to a protein and can provide new directions for the design of more 
potent inhibitors.
21
 For instance, this approach has been successfully used in the development of potent HIV 
protease inhibitors such as a cyclic urea reported by Lam et al.
22






Vara Prasad et al
24
. Taking into account the important stabilizing contribution that the interaction between 
WAT1 and either the natural substrate, the enolate intermediate 3 or enolate mimetics like compound 4c seem 
to have in their binding with the DHQ2 enzyme, we decided to explore the WAT1 binding pocket in the 
structure-based design of inhibitors of these enzymes. The possible enhanced binding affinity of mimetics of the 
enolate intermediate 3 was studied by promoting interactions with WAT1 or by displacement of WAT1, causing 
in the latter case a direct interaction with the active site residues. To this end, we report here the synthesis of 
new reversible competitive inhibitors of DHQ2 from H. pylori and M. tuberculosis, namely compounds 510 
(Figure 2), along with the results of inhibition studies (Figure 2). The crystal structures of DHQ2 from M. 
tuberculosis in complex with compounds 58 are also described. These structures show in detail the binding 
mode of these inhibitors and highlight the importance of the stereochemistry of the chiral center of the ligand 
side chains. Moreover, Molecular Dynamics (MD) simulation studies were carried out to study the binding 
mode of ligands 910 and to gain a better understanding of the binding determinants that enhance the inhibition 
potency.  
RESULTS AND DISCUSSION 
Synthesis of Compounds 5 and 6 
The synthesis of the target compound 5 was performed from the previously reported allylic bromide 12,
25
 which 
can be prepared in five steps from commercially available (–)-quinic acid (11) (Scheme 2). Firstly, nucleophilic 
substitution of allylic bromide 12 with sodium acetate in DMF gave acetate 13. Removal of the diacetal 
protecting group by treatment with aqueous trifluoroacetic acid afforded triol 10, which was converted into the 
desired acid 5 by basic hydrolysis of the methyl ester 10 and subsequent protonation with Amberlite IR-120 
(H
+
) ion-exchange resin. 
The synthesis of compound 6 was achieved by a Suzuki cross-coupling reaction between our previously 
reported vinyl triflate 15
26
 and vinyl boronic acid pinacol ester as the key step, followed by selective 
hydroboration-oxidation of the external double bond (Scheme 2). The cross-coupling reaction between vinyl 
 6 
triflate 15 and vinyl boronic acid pinacol ester was performed using Pd(PPh3)4 as the catalyst in the presence of 
aqueous potassium carbonate, to give the cross-coupling product 16 in excellent yield. Treatment of diene 16 
with borane tetrahydrofuran complex and subsequent reaction with sodium perborate gave alcohol 17. Removal 
of the TBS groups with TBAF gave the triol 18, which was converted to the desired acid 6 by basic hydrolysis 
and protonation with an ion-exchange resin. 
Synthesis of Compounds 710 
The synthesis of the target compounds 710 involved the preparation of the ,β-unsaturated ketone 19, which 
was obtained by a carbonylative Suzuki cross-coupling reaction between vinyl triflate 15
26
 and commercially 
available B-benzyl-9-BBN using Pd(dppf)Cl2 as catalyst and K3PO4 as base (Scheme 3). The desired hydroxyl 
acids 78 were obtained by 1,2-reduction of ,β-unsaturated ketones 19 or 20, the latter being obtained by 
treatment of 19 with TBAF. A difference in the diastereoselectivity of the 1,2-reduction was not observed on 
using either TBS-protected ,β-unsaturated ketone 19 or the corresponding deprotected ketone 20. Reduction of 
the two ,β-unsaturated ketones 19 and 20 gave a chromatographically separable mixture of alcohols in which 
the R-isomer was the major diastereoisomer in both cases. The stereochemistry of the reduction was confirmed 
by NOE experiments. Finally, the resulting lactones 23 and 24 were converted to the desired acids 7 and 8, 
respectively, in the same way as compound 6 from hydroxyl lactone 18. 
The desired chloro derivatives 9 and 10 were prepared from the corresponding R-hydroxyl and S-hydroxyl 
derivatives 22 and 21, respectively (Scheme 3). Treatment of alcohol 22 with triphenylphosphine and N-
chlorosuccinimide afforded chloride 27, which was converted to the desired acid 9 by deprotection of the TBS 
groups with TBAF followed by basic hydrolysis of the corresponding lactone 28 and protonation with an ion-
exchange resin. Finally, compound 21 was converted to the desired acid 10 in the same way as acid 9 from 
hydroxyl lactone 22. 
Inhibition Assay Results  
 7 
The inhibitory properties of compounds 510 against Mt-DHQ2 and Hp-DHQ2 were tested. These compounds 
proved to be reversible competitive inhibitors of both enzymes. The inhibition data (Ki), which were obtained 
from Dixon plots (1/v vs [I]), are summarized in Table 1.  
In general, with the exception of chloride 10 (Table 1, entry 6), all of the compounds proved to be modest 
competitive inhibitors of both enzymes with Ki values in the micromolar range. Compounds 5 and 6 showed Ki 
values against Mt-DHQ2 and Hp-DHQ2 in the range 1115 µM and 188282 µM, respectively. The increased 
length of the C3 hydroxyl chain in the latter inhibitors has a more pronounced effect on the inhibitory potency 
against the Hp-DHQ2 enzyme, while only slight differences were observed for the Mt-DHQ2 enzyme (Table 1, 
entries 1 and 2). The two hydroxyl derivatives 7 and 8 showed similar Ki values in the range 2737 µM against 
both enzymes (Table 1, entries 3 and 4). Compound 8, which has an R configuration in the C3 side chain, 
proved to be slightly more potent than its epimer. The most pronounced differences were found with the 
chlorides 9 and 10, which showed Ki values against Mt-DHQ2 and Hp-DHQ2 in the range 14.50.48 µM and 
40.510.5 µM, respectively (Table 1, entries 5 and 6). The results show that the replacement of the hydroxyl 
group in compound 8 by a chloride increases the inhibitory potency against Mt-DHQ2 and Hp-DHQ2 by more 
than 50- and 3-fold, respectively. Chloride 10, which has an R configuration on the C3 side chain, proved to be 
the most potent inhibitor of the series, with Ki values of 0.48 µM and 10.5 µM against Mt-DHQ2 and Hp-
DHQ2, respectively. It is worth highlighting that a recent Comparative Binding Energy (COMBINE) analysis 
carried out with a series of competitive reversible inhibitors of Hp-DHQ2 and Mt-DHQ2 enzymes allowed us to 
quantify the interactions that contribute most significantly to explaining the key differences between the two 
enzymes and to quantify the importance of ligand interactions at the interface pocket between chains, which is 
close to the active site.
27
 The latter pocket is involved in ligand efficiency and reveals significant differences 
between both enzymes (see Figures S7 and S8 of the Supporting Information). We believe that the significant 
differences in the inhibitory potency against both enzymes showed by the most potent inhibitor here reported, 
chloride 10, are due to the differences in the binding interactions with the residues involved in this pocket for 
both enzymes.  
 8 
In an effort to gain a further insight into the binding mode of these inhibitors and to identify the key binding 
interactions responsible for the experimentally obtained inhibition data, the crystal structures of Mt-DHQ2 in 
complex with compounds 58 were solved. The binding modes of compounds 910 with Mt-DHQ2 and the 
dynamic behavior of the key interactions identified in the binary complexes reported here were studied by MD 
simulation studies, the results of which are discussed below. 
Structural Studies 
The crystal structures of Mt-DHQ2 with the inhibitors 58 were obtained by soaking apo-Mt-DHQ2 crystals 
that were determined at 2.9, 2.2, 2.9 and 2.1 Å, respectively. All structures were determined by molecular 
replacement, using the previously described structure of Mt-DHQ2 bound to 3-hydroxyiminoquinic acid (PDB 
entry 1H0S)
28
 as a search model and the structures were refined (Table 2). All binary complexes Mt-DHQ2/58 
contain a single Mt-DHQ2 molecule in the crystallographic asymmetric unit (Figure 3). The structures were 
refined with good geometric parameters and clear electron density is visible for all amino acids with the 
exception of certain residues of the flexible substrate-covering loop, a situation that is not surprising given that 
this flexibility is essential for the function of the enzyme (Figure S1 of the Supporting Information). 
Mt-DHQ2/5 Binary Complex  The most remarkable features of this crystal structure are the interactions of the 
guanidinium group of the essential Arg19 with the C1 carboxylate group of 5 (electrostatic) and with the C3 
side chain hydroxyl group of 5 (hydrogen bonding) (Figure 3A).
29
 This arrangement of the side chain of Arg19 
near the carboxylate group of a ligand has not been seen before in any of the available DHQ2 crystal structures 
and it supports the recently suggested additional role of the essential arginine as the residue that triggers the 
release of the product from the active site. Thus, MD simulation studies carried out in our group on the binary 
complex Mt-DHQ2/2 indicated that the electrostatic interaction of the guanidinium group of Arg19 pulling on 
the carboxylate group in 2 is responsible for breaking the favorable interactions of the reaction product with the 
active site residues, specifically with Asn75, Ile102 and Ser103 residues.
13
 As a consequence, the product is 
expelled from the active site after a large conformational change involving residues 101112, which contain the 
conserved Arg108, Glu109 and Arg112 and 126130. As a result of the favorable electrostatic interaction 
between the Arg19 side chain and the carboxylate group of 5, the usual strong hydrogen bonding interactions 
 9 
involving the side chain NH2 group of Asn75 and the main chain NH group of Ser103 is lost as a consequence 
of the carboxylate rotation of ~51º (Figure 3A). This crystal structure also highlights the unusual position of 
WAT1 (WAT2001), which is displaced by 1.3 Å relative to its corresponding position in the binary complex 
Mt-DHQ2/6 (see below) towards the side chain of Asp88* of a symmetry-related neighboring enzyme subunit 
(Figure 3E). As a result of this displacement, the usual hydrogen bonding interaction with the carbonyl group of 
Pro11 residue is lost. 
Mt-DHQ2/6 Binary Complex  In this crystal structure, Arg19 is pointing towards the active site and its 
guanidinium group interacts with the phenolic group of Tyr24 and the C3 side chain hydroxyl group of ligand 6 
through two bridging water molecules (WAT2010 and WAT2081) (Figure 3B). Three water molecules join 
together the side chains of Arg19, Tyr24 and Asp88* residues. All of these attractive interactions facilitate the 
stabilization of the loop in the closed configuration and allow its description. In one of the possible 
arrangements of Asp88*, the side chain forms the usual salt bridge with the side chain of the conserved Arg112 
and in the other this salt bridge is partially broken because the carboxylate group is located close to WAT1 
(WAT2004). In this arrangement, WAT2004 is engaged in four hydrogen bonds, namely with the side chains of 
Asp88* and Asn10, the main chain amide of Gly78 and the carbonyl group of Pro11. 
Mt-DHQ2/7 Binary Complex  The benzyl group of inhibitor 7 seems to block the approach of the catalytic 
tyrosine to Arg108, thus preventing the formation of the hydrogen-bonding interaction required to close the 
active site upon substrate binding (Figure 3C). The position of this group seems to be controlled by a cation-π 
interaction between the phenyl moiety and the guanidinium group of Arg18, which is located in the loop. 
Furthermore, the hydroxyl group of the inhibitor side chain establishes a good hydrogen bond with the 
carboxylate group of Asp88* of the neighboring subunit (2.7 Å). Notably, and in contrast to the other crystal 
structures reported here, electron density was not observed for the structural water molecule. This finding is not 
surprising considering that a water molecule in the same position would sterically clash with the C3 side chain 
hydroxyl group of the ligand. As discussed below, the results of MD simulation studies also suggest that the 
structural water molecule is not compatible with the presence of the ligand. 
 10 
Mt-DHQ2/8 Binary Complex  Although the electron density is not conclusive, we modeled the side chain of 
Tyr24 to point inwards with the phenol group interacting with Arg108 through hydrogen-bonding with a 
bridging water molecule (WAT2010) (Figure 3D). As found in several binary complexes containing ligands 
with a C3 flexible chain substituted with an aromatic moiety, the side chain of Arg19 is probably displaced 
outside of the active site by the benzyl group of 8. In contrast to its epimer, compound 7 (see above), high 
electron density for WAT1 (WAT2004) is observed. Moreover, a comparison of this crystal structure with that 
of the Mt-DHQ2/4c binary complex (PDB entry 2Y71
18
) indicates that both structures are virtually identical, 
with rms differences of 0.155 Å after superposition of 124 C
α
-atom pairs (Figure 3F). In particular, the relative 
positions of their aromatic moieties and the oxygen atom of their C3 side chains with respect to WAT1 are very 
similar. Despite the structural similarities between these two binary complexes, compound 8 proved to be much 
less potent than compound 4c. However, we must take into account the important differences in the aromatic 
moieties of the two inhibitors (phenyl vs 5-methylbenzo[b]thiophenyl) and, therefore, their different interactions 
with the interface pocket close to the active site. Indeed, the results of our recent QSAR studies suggest that the 
inhibitory potency of the ligands against the Mt-DHQ2 enzyme can be enhanced by establishing favorable van 
der Waals interactions with Glu92* of the neighboring subunit.
27
 The larger size of the benzo[b]thiophenyl ring 
compared with the phenyl one favors these types of interactions (see Figure S2 of the Supporting Information). 
Finally, the R-configuration of the hydroxyl group in the C3 side chain of 8 allows it not only to establish a 
strong hydrogen-bonding interaction with WAT1 but also enables the appropriate positioning of the phenyl ring 
for a π-stacking interaction with the phenolic ring of the essential Tyr24 and an extended conformation of the 
flexible side chain is displayed. 
Molecular Dynamics Simulation Studies 
In order to analyze the relevance of the electrostatic interaction between the guanidinium group of Arg19 and 
the C1 carboxylate group in 5 and the hydrogen-bonding interactions with WAT1 in the reported complexes, 
the four binary complexes described here were subjected to 10 ns of dynamic simulation. Moreover, in order to 
gain further information concerning the inhibition results obtained on replacing the hydroxyl group in the C3 
 11 
side chains in 7 and 8 by a chloride, the binding mode of compounds 9 and 10 in the active site of the M. 
tuberculosis enzyme was also studied by MD simulation studies. These simulations were carried out on a 
catalytically active trimer
30
 in aqueous solution using the molecular mechanics force field AMBER.
31
 Unsolved 
residues were modeled using the web-based ModLoop server.
32
 For Mt-DHQ2/5 and Mt-DHQ2/7–8 binary 
complexes, the calculated loops locate the side chain of Tyr24 and Arg19 in a disposition in which they point 
outside of the active site in both cases. Simulations with Mt-DHQ2/9–10 binary complexes were carried out 
using the enzyme coordinates found in the crystal structures of Mt-DHQ2 in complex with their corresponding 
hydroxyl derivatives 7 and 8, with manual replacement of ligands 7–8 by 9–10, respectively.  
The MD simulation studies performed with the Mt-DHQ2/5 binary complex showed that the relative position of 
ligand 5 and Arg19 in the active site does not change significantly during the whole simulation (10 ns) (Figure 
S3 of the Supporting Information). The guanidinium group of Arg19 and the C1 carboxylate group of 5 interact 
directly during most of the simulation and, when they do not, the two residues are linked by a bridging water 
molecule. These results highlight that the interactions of the guanidinium group of Arg19 with the C1 
carboxylate group (electrostatic) and the primary hydroxyl group of 5 (hydrogen bonding) are very strong. More 
importantly, these results provide new evidence of the high mobility of the Arg19 side chain and thus the 
flexible loop in which it is located. This mobility enables not only control of the appropriate orientation of the 
essential tyrosine side chain by a cation-π interaction for the enolate generation, but also enables it to interact 
with the carboxylate group of the ligand. The latter interaction supports the hypothesis that the essential Arg19 
is also involved in the release of the reaction product from the active site.
13
 On the other hand, significant 
changes were not observed for the Mt-DHQ/6 binary complex during the whole simulation (Figure S3 of the 
Supporting Information). 
The computational studies carried out with Mt-DHQ2/7–8 binary complexes revealed the importance of the 
stereochemistry of the chiral center of the C3 side chain in 7–8 for their interaction with the WAT1 binding 
pocket (Figure 4). Thus, for the Mt-DHQ2/7 binary complex after 10 ns of simulation, WAT1 is displaced by 
1.5 Å relative to its usual position by the hydroxyl group of the C3 side chain in 7 (Figure 4A). In fact, when 
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the simulation studies were performed after manual removal of WAT1, the binding interactions of ligand 7 in 
the Mt-DHQ2/7 binary complex proved to be much more stable (Figure 4B). These findings are more clearly 
shown in the MD simulation studies conducted with ligand 9, in which the hydroxyl group has been replaced by 
a chloride. This simulation will be discussed below. In contrast, significant changes were not observed in the 
WAT1 binding pocket during the simulation on the Mt-DHQ2/8 binary complex, which shows once again the 
relevance of the hydrogen-bonding interaction of the ligand with WAT1 in the binding mode of ligand 8 (Figure 
4e).  
The binding modes of chlorides 9 and 10 were studied using the enzyme geometries found in the crystal 
structures of Mt-DHQ2 in complex with compounds 7 and 8. For the Mt-DHQ2/9 binary complex, similar 
behavior was observed to that in the simulation studies conducted with the hydroxyl derivative 7 (see above), 
although for ligand 9 the observed displacement of WAT1 from the WAT1 binding pocket by the chloride is 
clearly more pronounced. The MD simulation studies conducted with Mt-DHQ2/9 containing WAT1 showed 
that WAT1 is rapidly expelled from its usual position to be occupied by the chloride atom of ligand 9 (Figure 
4C). Large movements in the bottom of the interface pocket close to the active site were observed and this is 
mainly because WAT1 controls the correct positioning of the Asn12 side chain, which is also establishing a 
strong hydrogen bond with the side chain of His63* from the neighboring enzyme subunit. These results 
highlight the critical structural role of WAT1 in stabilizing the region of the active site between helix 310 H1 
and 3´, which contain residues 10–12 and 77–79, respectively. In fact, MD simulations conducted with the 
apo-form of the Mt-DHQ2 enzyme, i.e. in the absence of ligand, showed that WAT1 is not exchanged with the 
bulk solvent and does not undergo significant changes during the whole simulation (Figure S4 of the Supporting 
Information). Moreover, when the simulations of the Mt-DHQ2/9 binary complex were performed in the 
absence of WAT1, the binding interactions of the ligand proved to be very stable and the position of the 
chloride is anchored by two hydrogen-bonding interactions, one with the main chain amide of Gly78 and the 
other with the side chain of the conserved Asn12, and a halogen bond interaction with the carbonyl oxygen of 
Pro11 (Figure 4D).
33
 These results suggest that when the ligand occupies the position of WAT1, part of this 
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stabilization is lost because the positions of residues Asn12, Pro11 and Gly78 do not seem to be as efficiently 
‘frozen’ as they are when a water molecule is involved. 
In the case of the Mt-DHQ2/8 binary complex, the binding mode of inhibitor 10 in the active site of Mt-DHQ2 
obtained by MD simulation studies showed that the substituent of the C3 side chain (chloride) in 10 interacts 
with WAT1 by hydrogen-bonding (Figure 4F). However, unlike ligand 8, the chloride in 10 establishes two 
extra contacts, namely a halogen bond with the carbonyl oxygen of Pro11 and a CH…Cl interaction with the 
conserved Leu13. All of these interactions remained very stable during the whole simulation, which suggests 
that these interactions all contribute greatly to its binding with the enzyme and might explain the more than 50-
fold higher inhibitory potency of 10 in comparison to 8. The calculated binding free energies for both ligands 
also support these differences. The calculated binding free energies of compounds 9 and 10 in the active site of 
Mt-DHQ2 for the MD simulation studies conducted, using the Molecular Mechanics Poisson–Boltzmann 
Surface Area (MM/PBSA)
34
 approach in explicit water (GB) as implemented in Amber, also support the higher 
affinity of chloride 10 vs 9 as found experimentally (Table S1 of the Supporting Information). In addition, to 
examine temporal changes in the enzyme structure during the 10 ns of MD simulation, the root-mean-square 
deviation (rmsd) with respect to the starting structure was calculated for all complexes (Figure S5 of the 
Supporting Information). The obtained rmsd values are between 1.3˗2.7 Å and stabilize after about 0.2 ns. To 
determine the most deviated residues during the simulation, the rms fluctuations (rmsf) of the C
α
 atoms of the 
Mt-DHQ2 enzyme were calculated and plotted as a function of the residue number for the three chains (Figure 
S6 of the Supporting Information). As expected, the residues located in the substrate-covering loop, which 
flexibility is essential for the enzymatic activity, have the greatest rmsf values. 
When considered together, the results described above suggest that the binding affinity for the DHQ2 enzyme is 
enhanced for those ligands that can interact with WAT1, without causing changes in the WAT1 binding pocket, 
and promote extra interactions with the residues located in this pocket. The replacement of the hydroxyl group 
in 8 by a chloride not only enhanced the hydrogen-bonding interaction with WAT1 but also favored extra 
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contacts with the carbonyl group of Pro11 and the side chain of Leu13, a situation that may explain its markedly 
higher inhibitory potency. 
CONCLUSIONS AND FINAL REMARKS 
Several enol mimetics, compounds 5–10, of the reaction catalyzed by DHQ2, the third enzyme of the shikimic 
acid pathway, have been synthesized and tested as part of a structure-based design of inhibitors of DHQ2. These 
compounds were specifically designed to explore the WAT1 binding pocket, which has been suggested to play 
an important role in the stabilization of the natural substrate and the enolate intermediate 3 during the catalysis 
process. These compounds were synthesized by nucleophilic substitution or Suzuki cross-coupling from 
previously reported allylic bromide 12 or vinyl triflate 15. The reported compounds proved to be reversible 
competitive inhibitors of Mt-DHQ2 and Hp-DHQ2 with Ki values in the micromolar range. Chloride 10, which 
has an R-configuration in the C3 side chain, proved to be the most potent inhibitor of the series with a Ki value 
of 0.48 µM and 10.5 µM against Mt-DHQ2 and Hp-DHQ2, respectively. The results show that the replacement 
of the hydroxyl group (R configuration) of the C3 side chain in 8 by a chloride increases the inhibitory potency 
against Mt-DHQ2 and Hp-DHQ2 by more than 50- and 3-fold, respectively. 
The crystal structures of Mt-DHQ2 in complex with compounds 5–8 were solved at 2.9, 2.2, 2.9 and 2.1 Å, 
respectively. The structures of these complexes show that the hydroxyl group of the C3 side chain of 
compounds 5–6 and 8 does not occupy the WAT1 binding pocket. For the Mt-DHQ2/8 binary complex, this 
hydroxyl group interacts by hydrogen bonding with WAT1 while for the Mt-DHQ2/7 binary complex, 
displacement of the structural water molecule and direct interaction with the enzyme was observed. Moreover, 
the solved crystal structure of the Mt-DHQ2/5 binary complex showed an electrostatic interaction between the 
guanidinium group of the essential Arg19 and the carboxylate group of inhibitor 5 in the Mt-DHQ2/5 binary 
complex. This interaction has not been seen before in any DHQ2 crystal structure. This finding supports the 
recently proposed additional role of Arg19 as the residue that triggers the release of the product from the active 
site.
13
 The results of the structural and MD simulation studies reveal important differences in the binding mode 
interactions with WAT1 and the WAT1 binding pocket and these differences might explain the higher 
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inhibitory potency of the analogs with R configuration on the C3 side chain, i.e. compounds 8 and 10, in 
comparison to their epimers, compounds 7 and 9, which also bind to the active site with an extended 
conformation of this chain. This effect is particularly remarkable on replacing the OH group by a chloride. The 
results of MD simulation studies suggest that the OH/Cl groups of the C3 side chain in 7 and 9, respectively, 
occupy the position of WAT1 in the active site. In contrast, for their epimers, compounds 8 and 10, the OH/Cl 
groups interact by hydrogen bonding with WAT1 without expelling this molecule from the WAT1 binding 
pocket. In view of the structural and computational studies reported here, the inhibition potency against the 
DHQ2 enzyme would be favored by promoting interactions with WAT1, by avoiding the displacement of 
WAT1 and by promoting extra interactions with the residues located in the WAT1 binding pocket. In addition, 
those groups, which would be incorporated in the C3 side chain of the enolate mimetic with this purpose, must 
also allow an extended conformation of the C3 side chain in order to enable close contact of the aromatic 
moiety with the interface pocket between chains, which is highly involved in ligand efficiency.
27
 In view of our 
previous results with compounds 4,
18
 the replacement of the phenyl group in 10 by a larger size ring (naphtyl or 
benzo[b]thiophenyl) would enhance binding affinity of the ligand to the enzyme. Further chemical 
modifications of the reported acids are required to improve internalization into Mycobacterium tuberculosis 
cell. This is currently being carried out in our laboratories through a propyl ester prodrug approach as with 
previously reported O-alkyl derivatives 4.
18 
These computational studies also highlighted the key role of WAT1 
in the stabilization of the bottom of the interface pocket close to the active site and provide guidance for the 
future design of inhibitors against a recognized attractive target for the development of new antibacterial agents. 
EXPERIMENTAL SECTION 
General Procedures. All starting materials and reagents were commercially available and were used without 
further purification. 
1
H NMR spectra (250, 300, 400 and 500 MHz) and 
13
C NMR spectra (63, 75, 100 and 125 
MHz) were measured in deuterated solvents. J values are given in Hertz. NMR assignments were carried out by 
a combination of 1 D, COSY, and DEPT-135 experiments. FT-IR spectra were recorded as NaCl plates or KBr 






. UV spectra and enzyme assays were performed at 25 °C using 
 16 
1 cm path quartz cells in conjunction with a thermostatically controlled water bath. All procedures involving the 
use of ion-exchange resins were carried out at room temperature using Milli-Q deionized water. Amberlite IR-
120 (H
+
) (cation exchanger) was washed alternately with water, 10% NaOH, water, 10% HCl, and finally water 
before use. 
Methyl (1R,3S,4S,6R,9R)-7-acetoxymethyl-3,4-dimethoxy-3,4-dimethyl-9-trimethylsilyloxy-2,5-
dioxabicyclo[4.4.0]dec-7-en-9-carboxylate (13). A stirred solution of the bromide 12
25
 (300 mg, 0.64 mmol) 
in dry DMF (4.3 mL) was treated with sodium acetate (160 mg, 1.9 mmol). The mixture was stirred for 24 h at 
room temperature and diethyl ether and water were added. The organic layer was separated and the aqueous 
phase was extracted with diethyl ether (×2). The combined organic extracts were washed with brine. The 
organic extract was dried (anh. Na2SO4), filtered and concentrated under reduced pressure. The residue was 
purified by flash chromatography on silica gel, eluting with (40:60) diethyl ether/hexanes to give acetate 13 
(104 mg, 36%) as a colorless oil. Starting material (164 mg, 55%) was also recovered. Corrected yield: 46%. 
20][ D = +106.8º (c 1.0, CHCl3). 
1
H NMR (250 MHz, CDCl3) : 5.72 (s, 1H, H8), 4.74 (d, J = 13.8 Hz, 1H, 
CHHO), 4.66 (d, J = 13.8 Hz, 1H, CHHO), 4.23 (br d, J = 10.4 Hz, 1H, H6), 4.093.99 (m, 1H, H1), 3.74 (s, 
3H, OCH3), 3.27 (s, 3H, OCH3), 3.26 (s, 3H, OCH3), 2.212.09 (m, 2H, CH2-10), 2.06 (s, 3H, CH3), 1.31 (s, 
3H, CH3), 1.30 (s, 3H, CH3) and 0.12 (s, 9H, Si(CH3)3) ppm. 
13
C NMR (63 MHz, CDCl3) :173.8 (C), 170.5 
(C), 136.0 (C), 126.0 (CH), 100.5 (C), 100.0 (C), 75.8 (C), 69.4 (CH), 65.6 (CH), 62.6 (CH2), 52.7 (OCH3), 
48.1 (OCH3), 48.0 (OCH3), 37.7 (CH2), 21.0 (CH3), 18.0 (CH3), 17.9 (CH3) and 2.0 (3×CH3) ppm. IR (film) : 
1744 (CO) cm
-1
. MS (ESI) m/z = 469 (MNa
+
). HRMS calcd for C20H34O9SiNa (MNa
+
): 469.1864; found, 
469.1870.  
Methyl (1R,4S,5R)-3-acetoxymethyl-1,4,5-trihydroxycyclohex-2-en-1-carboxylate (14). A solution of the 
acetal 13 (74 mg, 0.16 mmol) in a 20:1 (v/v) mixture of TFA/H2O (0.3 mL) was stirred at 0 ºC for 15 min. 
Solvents were removed under reduced pressure and the crude residue was purified by flash chromatography on 
silica gel, eluting with (40:60) ethyl acetate/hexanes to give triol 14 (28 mg, 68%) as a colorless oil. 
20][ D = 
+49.3º (c 1.9, CH3OH). 
1
H NMR (250 MHz, CD3OD) : 5.73 (br s, 1H, H2), 4.78 (d, J = 13.7 Hz, 1H, CHHO), 
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4.61 (d, J = 13.7 Hz, 1H, CHHO), 4.003.85 (m, 2H, H4+H5), 3.74 (s, 3H, OCH3), 2.08 (s, 3H, CH3) and 2.02 
(m, 2H, CH2-6) ppm. 
13
C NMR (63 MHz, CD3OD) :176.1 (C), 172.4 (C), 140.5 (C), 126.1 (CH), 74.0 (C), 
73.9 (CH), 70.6 (CH), 64.9 (OCH2), 53.1 (OCH3), 40.5 (CH2) and 20.8 (CH3) ppm. IR (film) : 3419 (OH) and 
1732 (CO) cm
-1
. MS (ESI) m/z = 283 (MNa
+
). HRMS calcd for C11H16O7Na (MNa
+
): 283.0788; found, 
283.0789.  
(1R,4R,5R)-1,4,5-Trihydroxy-3-hydroxymethylcyclohex-2-en-1-carboxylic acid (5). A solution of the ester 
14 (19 mg, 0.07 mmol) in THF (0.6 mL) was treated at room temperature with an aqueous solution of LiOH 
(0.07 mL, 0.17 mmol, 2.5M). The mixture was stirred for 1 h, the THF was removed under reduced pressure 
and water was added. The aqueous layer was washed with ethyl acetate (×3) and then treated with Amberlite 
IR-120 (H
+
) until pH 6. The resin was filtered and washed with Milli-Q water. The filtrate and the washings 
were lyophilized to give acid 5 (16 mg, 99%) as a yellow oil. 
20][ D = 80.7º (c 1.2, CH3OH). 
1
H NMR (250 
MHz, CD3OD) : 5.68 (s, 1H, H2), 4.18 (s, 2H, OCH2), 3.99 (d, J = 6.9 Hz, 1H, H4), 3.89 (m, 1H, H5) and 2.07 
(m, 2H, CH2-6) ppm. 
13
C NMR (63 MHz, CD3OD) :179.3 (C), 143.7 (C), 125.2 (CH), 74.1 (C), 73.3 (CH), 
71.1 (CH), 63.3 (OCH2) and 39.8 (CH2) ppm. IR (film) : 3434 (OH) and 1730 (CO) cm
-1
. MS (ESI) m/z = 203 
(M‒H). HRMS calcd for C8H11O6 (M‒H): 203.0561; found, 203.0568.  
(1R,4S,5R)-1,4-Di(tert-butyldimethylsilyloxy)-3-vinylcyclohex-2-en-1,5-carbolactone (16). A Schlenk tube 
was charged with triflate 15
26 
(500 mg, 0.94 mmol), Pd(PPh3)4 (115 mg, 0.1 mmol), K2CO3 (2.54 mL, 2.79 
mmol, 1.1 M) and vinylboronic acid pinacol ester (24 µL, 1.4 mmol) in dry dioxane (11.6 mL). The resultant 
suspension was deoxygenated and heated at 100 ºC for 2 h under argon. The mixture was allowed to cool to 
room temperature. The suspension was filtered over Celite and the residue was washed with diethyl ether. The 
filtrate and washings were concentrated under reduced pressure to yield an oil, which was purified by flash 
chromatography on silica gel, eluting with (25:75) dichloromethane/hexanes, to give diene 16 (318 mg, 82%) as 
a colorless oil. 
20][ D = 193.7º (c 1.6, CHCl3). 
1
H NMR (300 MHz, CDCl3) : 6.14 (dd, J = 17.6 and 11.0 Hz, 
1H, CH=CH2), 5.98 (d, J = 1.4 Hz, 1H, H2), 5.37 (dd, J = 17.6 and 0.9 Hz, 1H, CH=CHH), 5.17 (dd, J = 11.0 
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and 0.9 Hz, 1H, CH=CHH), 4.56 (dd, J = 5.8 and 3.4 Hz, 1H, H5), 4.37 (d, J = 3.4 Hz, 1H, H4), 2.44 (d, J = 
10.6 Hz, 1H, H6ax), 2.35 (ddd, J = 10.6, 5.8 and 1.9 Hz, 1H, H6eq), 0.93 (s, 9H, C(CH3)3), 0.89 (s, 9H, 
C(CH3)3), 0.19 (s, 3H, CH3), 0.16 (s, 6H, 2×CH3) and 0.15 (s, 3H, CH3) ppm. 
13
C NMR (75 MHz, CDCl3) 
:175.6 (C), 136.8 (C), 134.7 (CH), 133.8 (CH), 116.3 (CH2), 75.9 (CH), 75.1 (C), 66.0 (CH), 37.1 (CH2), 25.8 
(C(CH3)3), 25.8 (C(CH3)3), 18.2 (2×C(CH3)3), 2.9 (2×CH3), 3.9 (CH3) and 4.4 (CH3) ppm. IR (film) : 
1801 (CO) cm
-1
. MS (ESI) m/z = 433 (MNa
+
). HRMS calcd for C21H38O4Si2Na (MNa
+
): 433.2201; found, 
433.2178.  
(1R,4S,5R)-1,4-Di(tert-butyldimethylsilyloxy)-3-(2-hydroxy)ethylcyclohex-2-en-1,5-carbolactone (17). A 
stirred solution of diene 16
 
(50 mg, 0.12 mmol) in dry THF (3 mL), under argon at 0 ºC, was treated with a 
BH3-THF solution (1.22 mL, 1.22 mmol). The mixture was stirred for 1 h. An aqueous solution of NaBO3 (3 
mL, 1.22 mmol, 0.4 M) was added and the resulting solution was stirred for 2 h at this temperature. The mixture 
was warmed up to room temperature and ethyl acetate and water were added. The organic layer was separated 
and the aqueous layer was extracted with ethyl acetate (×2). The combined organic extracts were dried (anh. 
Na2SO4), filtered and concentrated under reduced pressure. The residue was purified by flash chromatography 
on silica gel, eluting with (50:50) diethyl ether/hexanes, to give alcohol 17 (18 mg, 35%) as a colorless oil. 
20][ D
= +132.8º (c 1.8, CHCl3). 
1
H NMR (300 MHz, CDCl3) : 5.84 (br d, J = 1.1 Hz, 1H, H2), 4.48 (m, 1H, H5), 
4.06 (d, J = 3.1 Hz, 1H, H4), 3.72 (td, J = 6.5 and 1.7 Hz, 2H, CH2O), 2.332.31 (m, 4H, 2×CH2), 1.57 (s, 1H, 
OH), 0.92 (s, 9H, C(CH3)3), 0.91 (s, 9H, C(CH3)3), 0.18 (s, 3H, CH3), 0.16 (s, 3H, CH3), 0.15 (s, 3H, CH3) and 
0.14 (s, 3H, CH3) ppm. 
13
C NMR (75 MHz, CDCl3) :176.1 (C), 136.1 (C), 133.1 (CH), 76.0 (CH), 74.8 (C), 
68.2 (CH), 61.0 (CH2), 37.2 (CH2), 35.2 (CH2), 25.8 (C(CH3)3), 25.7 (C(CH3)3), 18.1 (C(CH3)3), 18.0 
(C(CH3)3), 2.9 (CH3), 2.9 (CH3), 4.5 (CH3) and 4.5 (CH3) ppm. IR (film) : 3421 (OH) and 1794 (CO) 
cm
-1
. MS (ESI) m/z = 451 (MNa
+
). HRMS calcd for C21H40O5Si2Na (MNa
+
): 451.2306; found, 451.2305.  
(1R,4S,5R)-1,4-Dihydroxy-3-(2-hydroxy)ethylcyclohex-2-en-1,5-carbolactone (18). Tetrabutylammonium 
fluoride (0.5 mL, 0.47 mmol, ca 1.0 M in THF) was added to a stirred solution of the silyl ether 17 (82 mg, 0.19 
mmol) in dry THF (2.7 mL) under argon at 0 ºC. The mixture was stirred for 2 h and water and ethyl acetate 
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were added. The aqueous layer was acidified with dilute HCl (10%) and the organic layer was separated. The 
aqueous phase was extracted with ethyl acetate (x2). The combined organic extracts were dried (anh. Na2SO4), 
filtered and concentrated under reduced pressure. The residue was purified by flash chromatography on silica 
gel, eluting with (80:20) ethyl acetate-hexanes to yield triol 18 (24 mg, 63%) as a colorless oil. 
20][ D = 232º (c 
1.5, MeOH). 
1
H NMR (300 MHz, CD3OD) : 5.83 (br s, 1H, H2), 4.59 (ddd, J = 5.2, 3.2 and 0.8 Hz, 1H, H5), 
4.03 (d, J = 3.2 Hz, 1H, H4), 3.68 (dd, J = 7.0 and 2.2 Hz, 1H, OCHH), 3.66 (dd, J = 7.0 and 2.8 Hz, 1H, 
OCHH) and 2.442.23 (m, 4H, 2×CH2) ppm. 
13
C NMR (63 MHz, CD3OD) :179.1 (C), 138.7 (C), 132.3 (CH), 
77.9 (CH), 74.0 (C), 68.0 (CH), 61.3 (CH2), 37.4 (CH2) and 36.4 (CH2) ppm. IR (film) : 3366 (OH) and 1778 
(CO) cm
-1
. MS (ESI) m/z = 223 (MNa
+
). HRMS calcd for C9H12O5Na (MNa
+
): 223.0577; found, 223.0571.  
(1R,4R,5R)-1,4,5-Trihydroxy-3-(2-hydroxy)ethylcyclohex-2-ene-1-carboxylic acid (6). A solution of the 
lactone 18 (15 mg, 0.08 mmol) in THF (0.8 mL) and aqueous lithium hydroxide (0.4 mL, 0.2 mmol, 0.5 M) was 
stirred at room temperature for 1 h. Water was added and the THF was removed under reduced pressure. The 
resulting aqueous solution was washed with ethyl acetate (×2) and the aqueous extract was treated with 
Amberlite IR-120 (H
+
) until pH 6. The resin was filtered off and washed with Milli-Q water. The filtrate and the 
washings were lyophilized to give acid 6 (12 mg, 75%) as a colorless oil. 
20][ D = 63º (c 1.2, H2O). 
1
H NMR 
(300 MHz, D2O) : 5.60 (br s, 1H, H2), 4.05 (d, J = 8.0 Hz, 1H, H4), 3.92 (m, 1H, H5), 3.75 (t, J = 6.5 Hz, 2H, 
OCH2), 2.55 (m, 1H, CHH), 2.34 (m, 1H, CHH) and 2.182.07 (m, 2H, CH2) ppm. 
13
C NMR (63 MHz, D2O) 
:178.8 (C), 142.2 (C), 124.9 (CH), 73.9 (C), 73.6 (CH), 69.9 (CH), 60.2 (CH2), 39.4 (CH2) and 35.1 (CH2) 
ppm. IR (film) : 3339 (OH) and 1708 (CO) cm
-1
. MS (ESI) m/z = 217 (MH). HRMS calcd for C9H13O6 
(MH): 217.0708; found, 217.0714. 
Carbonylation of triflate 15. A stirred solution of triflate 15
22
 (813 mg, 1.52 mmol), Pd(dppf)Cl2 (86 mg, 0.11 
mmol) in dry THF (150 mL) saturated with a continuous flow of carbon monoxide was treated with B-benzyl-9-
BBN (8.25 mL, 4.13 mmol, ca. 0.5M in THF) and an aqueous solution of K3PO4 (4 mL, 4 mmol, 1M). The 
resulting mixture was heated at 55 ºC for 4 h. The mixture was allowed to cool to room temperature, the organic 
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solvent was removed under reduced pressure and the mixture was diluted with diethyl ether and water. The 
organic layer was separated and the organic phase was extracted with diethyl ether (×2). The combined organic 
extracts were dried (anh. Na2SO4), filtered and concentrated under reduced pressure. The residue was purified 
by flash chromatography, eluting with (5:95) diethyl ether/hexanes to give ketone 19 (385 mg, 51%) as a white 
solid. The corresponding cross-coupling product was also obtained in 13% yield (93 mg). Data for 19: White 
solid. Mp: 8081 ºC. 
20][ D = ‒15.8º (c1.0, CHCl3). 
1
H NMR (400 MHz, CDCl3) δ: 7.30 (m, 2H, 2×ArH), 7.24 
(m, 1H, ArH), 7.17 (d, J = 7.3 Hz, 2H, 2×ArH), 6.88 (d, J = 0.9 Hz, 1H, H2), 4.68 (d, J = 3.4 Hz, 1H, H4), 4.55 
(dd, J = 5.7 and 3.5 Hz, 1H, H5), 3.92 (br d, J = 15.7 Hz, 1H, CHHPh), 3.89 (br d, J = 15.7 Hz, 1H, CHHPh), 
2.48 (d, J = 10.9 Hz, 1H, H6ax), 2.38 (m, 1H, H6eq), 0.94 (s, 9H, C(CH3)3), 0.83 (s, 9H, C(CH3)3), 0.17 (s, 3H, 
CH3), 0.17 (s, 3H, CH3), 0.12 (s, 3H, CH3) and 0.06 (s, 3H, CH3) ppm. 
13
C NMR (75 MHz, CDCl3) : 196.2 
(C), 174.4 (C), 144.9 (CH), 138.5 (C), 134.0 (C), 129.4 (2×CH), 128.9 (2×CH), 127.1 (CH), 75.7 (CH), 75.2 
(C), 63.5 (CH), 45.0 (CH2), 36.4 (CH2), 25.8 (C(CH3)3), 25.7 (C(CH3)3), 18.1 (C(CH3)3), 18.1 (C(CH3)3), 3.0 
(2×CH3), 4.8 (CH3) and 5.1 (CH3) ppm. IR (KBr) υ: 1801 (CO) and 1684 (CO) cm
-1
. MS (ESI) m/z = 525 
(MNa
+
). HRMS calcd for C27H42O5Si2Na (MNa
+
): 525.2463; found, 525.2449. Data for cross-coupling product 
[(1R,4R,5R)-1,4-di(tert-butyldimethylsilyloxy)-3-benzylcyclohex-2-en-1,5-carbolactone]: Colorless oil. 
20][ D = 
‒16.2º (c1.0, CHCl3). 
1
H NMR (300 MHz, CDCl3) δ: 7.29 (m, 2H, 2×ArH), 7.21 (m, 1H, ArH), 7.09 (d, J = 7.1 
Hz, 2H, 2×ArH), 5.54 (s, 1H, H2), 4.48 (m, 1H, H5), 4.02 (d, J = 3.0 Hz, 1H, H4), 3.46 (d, J = 16.1 Hz, 1H, 
CHHPh), 3.28 (d, J = 16.1 Hz, 1H, CHHPh), 2.34 (m, 2H, CH2-6), 0.93 (s, 9H, C(CH3)3), 0.87 (s, 9H, 
C(CH3)3), 0.10 (s, 6H, 2×CH3), 0.09 (s, 3H, CH3) and 0.06 (s, 3H, CH3) ppm. 
13
C NMR (100 MHz, CDCl3) : 
176.0 (C), 138.8 (C), 137.3 (C), 132.7 (CH), 129.2 (2×CH), 128.5 (2×CH), 126.5 (CH), 75.9 (CH), 74.8 (C), 
67.5 (CH), 38.2 (CH2), 37.4 (CH2), 25.7 (C(CH3)3), 25.6 (C(CH3)3), 17.9 (C(CH3)3), 17.9 (C(CH3)3), 3.1 
(2×CH3), 4.5 (CH3) and 4.7 (CH3) ppm. IR (film) υ: 1805 (C=O) cm
-1
. MS (ESI) m/z = 497 (MNa
+
). HRMS 
calcd for C26H42O4Si2Na (MNa
+
): 497.2514; found, 497.2523. 
(1R,4R,5R)-1,4-Dihydroxy-3-(2-benzylacetyl)cyclohex-2-en-1,5-carbolactone (20). A stirred solution of the 
silylether 19 (385 mg, 0.77 mmol) in dry THF (7.7 mL), under argon at 0 ºC, was treated with 
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tetrabutylammonium fluoride (1.92 mL, 1.92 mmol, ca. 1.0 M in THF). The mixture was stirred for 30 min, 
saturated NH4Cl was added and the organic layer was extracted with diethyl ether (×3). The combined organic 
extracts were dried (anh. Na2SO4), filtered and concentrated under reduced pressure. The crude product was 
purified by flash chromatography on silica gel, eluting with (1:1:1) diethyl ether/acetone/hexanes to give diol 20 
(60 mg, 29%) as a white solid. 
20][ D = ‒15.0º (c1.0, CH3OH). Mp: 172173 ºC. 
1
H NMR (300 MHz, CD3OD) δ: 
7.29 (m, 2H, 2×ArH), 7.23 (m, 1H, ArH), 7.18 (m, 2H, 2×ArH), 7.13 (br s, 1H, H2), 4.69 (m, 1H, H5), 4.59 (d, 
J = 3.4 Hz, 1H, H4), 4.07 (d, J = 16.2 Hz, 1H, CHHPh), 4.00 (d, J = 16.2 Hz, 1H, CHHPh) and 2.41 (m, 2H, 
CH2-6) ppm. 
13
C NMR (100 MHz, CH3OD) : 198.9 (C), 177.1 (C), 145.5 (CH), 139.6 (C), 135.7 (C), 130.6 
(2×CH), 129.5 (2×CH), 127.8 (CH), 77.4 (CH), 74.4 (C), 64.2 (CH), 45.6 (CH2) and 36.7 (CH2) ppm. IR (KBr) 
υ: 3457 (OH), 3420 (OH), 1766 (CO) and 1680 (CO) cm
-1
. MS (ESI) m/z: 297 (MNa
+
). HRMS calcd for 
C15H14O5Na (MNa
+
): 297.0733; found, 297.0736.  
Reduction of α,β-unsaturated 19. A stirred solution of the ketone 19 (100 mg, 0.20 mmol) in dry THF (2 mL), 
under argon at 0 ºC, was treated with cerium(III) chloride heptahydratate (127 mg, 0.60 mmol), sodium 
borohydride (3.2 mg, 0.08 mmol) and methanol (5 drops). The mixture was stirred for 1 h and water and diethyl 
ether were added. The organic layer was separated and the aqueous layer was extracted with diethyl ether (×3). 
The combined organic extracts were dried (anh. Na2SO4), filtered and concentrated under reduced pressure. The 
crude product was purified by flash chromatography on silica gel, eluting with (5:5:90) diethyl 
ether/dichloromethane/hexanes to give alcohol 21 (28 mg, 28%) and alcohol 22 (51 mg, 51%). Data for 
(1R,4R,5R)-1,4-di(tert-butyldimethylsilyloxy)-3-[(1S)-1-hydroxy-2-phenyl]ethylcyclohex-2-en-1,5-
carbolactone (21). White solid. 20][ D = ‒ 12.3º (c1.0, CHCl3). 
1
H NMR (300 MHz, CDCl3) δ: 7.34‒7.24 (m, 3H, 
3×ArH), 7.14 (m, 1H, ArH), 6.03 (s, 1H, H2), 4.47 (q, J = 3.2 Hz, 1H, H5), 4.43 (m, 1H, CHOH), 4.09 (d, J = 
3.3 Hz, 1H, H4), 2.94 (dd, J = 13.6 and 5.0 Hz, 1H, CHHPh), 2.79 (dd, J = 13.6 and 7.9 Hz, 1H, CHHPh), 2.33 
(d, J = 2.6 Hz, 2H, CH2-6), 0.92 (s, 9H, C(CH3)3), 0.91 (s, 9H, C(CH3)3), 0.18 (s, 3H, CH3), 0.16 (s, 3H, CH3), 
0.14 (s, 3H, CH3) and 0.12 (s, 3H, CH3) ppm. 
13
C NMR (63 MHz, CDCl3) : 175.7 (C), 141.0 (C), 136.9 (C), 
131.6 (CH), 129.7 (2×CH), 128.8 (2×CH), 127.0 (CH), 75.9 (CH), 74.9 (C), 70.9 (CH), 66.6 (CH), 43.0 (CH2), 
 22 
37.1 (CH2), 25.8 (C(CH3)3), 25.8 (C(CH3)3), 18.2 (C(CH3)3), 18.0 (C(CH3)3), 2.9 (2×CH3) and 4.3 (2×CH3) 
ppm. IR (KBr) υ: 3421 (OH) and 1792 (CO) cm
-1
. MS (ESI) m/z = 597 (MNa
+
). HRMS calcd for 
C27H44O5Si2Na (MNa
+
): 527.2619; found, 527.2624. Data for (1R,4R,5R)-1,4-di(tert-butyldimethylsilyloxy)-3-
[(1R)-1-hydroxy-2-phenyl]ethylcyclohex-2-en-1,5-carbolactone (22). Colorless oil. 20][ D = ‒37.2º (c1.0, 
CHCl3). 
1
H NMR (300 MHz, CDCl3) δ: 7.34‒7.23 (m, 3H, 3×ArH), 7.18 (m, 2H, 2×ArH), 5.95 (s, 1H, H2), 
4.51 (q, J = 3.1 Hz, 1H, H5), 4.42 (d, J = 3.2 Hz, 1H, H4), 4.33 (m, 1H, CHOH), 3.02 (dd, J = 13.7 and 4.5 Hz, 
1H, CHHPh), 2.83 (dd, J = 13.7 and 8.7 Hz, 1H, CHHPh), 2.35 (d, J = 2.6 Hz, 2H, CH2-6), 0.93 (s, 9H, 
C(CH3)3), 0.91 (s, 9H, C(CH3)3), 0.19 (s, 3H, CH3), 0.18 (s, 3H, CH3), 0.15 (s, 3H, CH3) and 0.12 (s, 3H, CH3) 
ppm. 
13
C NMR (63 MHz, CDCl3) : 175.5 (C), 139.5 (C), 137.7 (C), 133.2 (CH), 129.5 (2×CH), 128.8 (2×CH), 
126.8 (CH), 75.9 (CH), 74.8 (C), 72.3 (CH), 66.6 (CH), 42.1 (CH2), 37.1 (CH2), 25.9 (C(CH3)3), 25.7 
(C(CH3)3), 18.2 (C(CH3)3), 18.0 (C(CH3)3), 2.9 (2×CH3), 4.3 (CH3) and 4.4 (CH3) ppm. IR (film) υ: 3417 
(OH) and 1791 (CO) cm
-1
. MS (ESI) m/z = 527 (MNa
+
). HRMS calcd for C27H44O5Si2Na (MNa
+
): 527.2619; 
found, 527.2625.  
Reduction of α,β-unsaturated ketone 20. A stirred solution of the ketone 20 (43 mg, 0.16 mmol) in dry THF 
(4 mL), under argon at 0 ºC, was treated with cerium(III) chloride heptahydratate (59 mg, 0.16 mmol), sodium 
triacetoxyborohydride (110 mg, 0.52 mmol) and methanol (5 drops). The mixture was stirred for 1 h and water 
and ethyl acetate were added. The organic layer was separated and the aqueous layer was extracted with ethyl 
acetate (×3). The combined organic extracts were dried (anh. Na2SO4), filtered and concentrated under reduced 
pressure. The crude product was purified by HPLC on a Luna phenomenex C18 column eluting with 
acetonitrile/water (48:52) at 7 mL·min
–1
 to give triols 23 (10 mg, 26%) and 24 (22 mg, 51%), both as white 
solids. Data for (1R,4R,5R)-1,4-dihydroxy-3-[(1S)-1-hydroxy-2-phenylacetyl]cyclohex-2-en-1,5-carbolactone 
(23). White solid. 
20][ D = ‒18.1º (c1.0, CH3OH). Mp: 170171 ºC. 
1
H NMR (250 MHz, CD3OD) δ: 7.28‒7.14 
(m, 5H, 5×ArH), 5.90 (s, 1H, H2), 4.61 (q, J = 3.2 1H, H5), 4.36 (m, 2H, H4+CHOH), 2.97 (dd, J = 13.7 and 
5.2 Hz, 1H, CHHPh), 2.84 (d, J = 13.7 and 8.3 Hz, 1H, CHHPh) and 2.32 (m, 2H, CH2-6) ppm. 
13
C NMR (63 
MHz, CH3OD) : 178.6 (C), 142.2 (C), 139.9 (C), 132.0 (CH), 130.5 (2×CH), 129.2 (2×CH), 127.2 (CH), 77.8 
 23 
(CH), 74.0 (C), 73.9 (CH), 66.6 (CH), 43.0 (CH2) and 37.5 (CH2) ppm. IR (KBr) υ: 3402 (OH), 3418 (OH) and 
1765 (CO) cm
-1
. MS (ESI) m/z = 299 (MNa
+
). HRMS calcd for C15H16O5Na (MNa
+
): 299.0890; found, 
299.0891. Data for (1R,4R,5R)-1,4-dihydroxy-3-[(1R)-1-hydroxy-2-phenylacetyl]cyclohex-2-en-1,5-
carbolactone (24). White solid. 
20][ D = ‒7.8º (c1.0, CH3OH). Mp: 138139 ºC. 
1
H NMR (250 MHz, CD3OD) δ: 
7.27‒7.15 (m, 5H, 5×ArH), 5.96 (s, 1H, H2), 4.57 (m, 1H, H5), 4.50 (m, 1H, CHOH), 4.02 (d, J = 2.7 Hz, 1H, 
H4), 2.97 (dd, J = 13.5 and 5.2 Hz, 1H, CHHPh), 2.79 (dd, J = 13.5 and 7.3 Hz, 1H, CHHPh) and 2.28 (m, 2H, 
CH2-6) ppm. 
13
C NMR (63 MHz, CH3OD) : 178.8 (C), 143.7 (C), 139.4 (C), 130.9 (CH), 130.7 (2×CH), 129.2 
(2×CH), 127.2 (CH), 78.0 (CH), 74.1 (C), 72.1 (CH), 66.4 (CH), 43.8 (CH2) and 37.3 (CH2) ppm. IR (KBr) υ: 
3416 (OH) and 1781 (CO) cm
-1
. MS (ESI) m/z = 299 (MNa
+
). HRMS calcd for C15H16O5Na (MNa
+
): 299.0890; 
found, 299.0882.  
(1R,4R,5R)-1,4,5-Trihydroxy-3-[(1S)-1-hydroxy-2-phenylethyl]cyclohex-2-en-1-carboxylic acid (7). A 
solution of carbolactone 23 (10.5 mg, 0.04 mmol) in THF (0.4 mL) and aqueous lithium hydroxide (0.1 mL, 
0.10 mmol, 1 M) was stirred at room temperature for 30 min. Water was added and the THF was removed 
under reduced pressure. The resulting aqueous solution was washed with diethyl ether (×3) and the aqueous 
extract was treated with Amberlite IR-120 (H
+
) until pH 6. The resin was filtered off and washed with Milli-Q 
water. The filtrate and the washings were lyophilized to give acid 7 (10 mg, 90%) as a white solid. 
20][ D = ‒6.0º 
(c1.0, MeOH). Mp: 132133 ºC. 
1
H NMR (250 MHz, D2O) δ: 7.437.29 (m, 5H, 5×ArH), 5.78 (s, 1H, H2), 
4.59 (dd, J = 9.2 and 4.5 Hz, 1H, CHOH), 4.27 (d, J = 7.5 Hz, 1H, H4), 3.97 (q, J = 7.5 Hz, 1H, H5), 3.12 (dd, J 
= 13.9 and 4.5 Hz, 1H, CHHPh), 2.90 (dd, J = 13.9 and 9.2 Hz 1H, CHHPh) and 2.11 (d, J = 7.5 Hz, 2H, CH2-
6) ppm. 
13
C NMR (63 MHz, D2O) : 179.4 (C), 144.3 (C), 139.2 (C), 129.8 (2×CH), 129.0 (2×CH), 126.9 
(CH), 125.7 (CH), 73.7 (C), 72.5 (2×CH), 69.9 (CH), 41.7 (CH2) and 38.6 (CH2) ppm. IR (KBr) υ: 3367 (OH) 
and 1721 (CO) cm
-1
. MS (ESI) m/z = 293 (MH). HRMS calcd for C15H17O6 (MH): 293.1031; found, 
293.1029. 
(1R,4R,5R)-1,4,5-Trihydroxy-3-[(1R)-1-hydroxy-2-phenylethyl]cyclohex-2-en-1-carboxylic acid (8). A 
solution of carbolactone 24 (7 mg, 0.025 mmol) in THF (0.4 mL) and aqueous lithium hydroxide (0.09 mL, 
 24 
0.09 mmol, 1 M) was stirred at room temperature for 30 min. Water was added and the THF was removed 
under reduced pressure. The resulting aqueous solution was washed with diethyl ether (×3) and the aqueous 
extract was treated with Amberlite IR-120 (H
+
) until pH 6. The resin was filtered off and washed with Milli-Q 
water. The filtrate and the washings were lyophilized to give acid 8 (5 mg, 67%) as a white solid. 
20][ D = ‒1.1º 
(c1.0, MeOH). Mp: 9596 ºC. NMR (300 MHz, D2O) δ: 7.39 (m, 2H, 2×ArH), 7.32 (m, 23H, 3×ArH), 5.70 (s, 
1H, H2), 4.08 (d, J = 7.8 Hz, 1H, H4), 3.95 (m, 1H, H5), 3.61 (m, 1H, CHOH), 3.16 (dd, J = 14.0 and 4.0 Hz, 
1H, CHHPh), 2.74 (dd, J = 14.0 and 8.4 Hz 1H, CHHPh) and 2.14 (m, 2H, CH2-6) ppm. 
13
C NMR (63 MHz, 
D2O) : 178.5 (C), 146.0 (C), 138.6 (C), 130.0 (2×CH), 128.9 (2×CH), 127.0 (CH), 122.4 (CH), 73.6 (C), 72.6 
(CH), 70.8 (CH), 69.9 (CH), 41.7 (CH2) and 38.6 (CH2) ppm. IR (KBr) υ: 3430 (OH) and 1721 (CO) cm
-1
. MS 
(ESI) m/z = 293 (MH). HRMS calcd for C15H17O6 (MH): 293.1031; found, 293.1029. 
(1R,4R,5R)-1,4-Di(tert-butyldimethylsilyloxy)-3-[(1R)-1-chloro-2-phenyl]ethylcyclohex-2-en-1,5-
carbolactone (25). A stirred solution of the alcohol 21 (112 mg, 0.22 mmol) in dry THF (10 mL), at room 
temperature and under argon, was treated with N-chlorosuccinimide (59 mg, 0.44 mmol) and 
triphenylphosphine (87 mg, 0.33 mmol). The reaction mixture was stirred for 1 h and the solvent was removed 
under reduced pressure. The crude product was purified by flash chromatography on silica gel, eluting with 
diethyl ether/hexanes (5:95), to give chloride 25 (48 mg, 42%) as a white foam. 20][ D = 41.7 (c 1.0, CHCl3). 
1
H 
NMR (250 MHz, CDCl3) : 7.357.18 (m, 5H, 5×ArH), 6.10 (s, 1H, H2), 4.66 (dd, J = 9.3 and 5.3 Hz, 1H, 
CHCl), 4.53 (dd, J = 5.6 and 3.2 Hz,1H, H5), 4.44 (d, J = 3.2 Hz, 1H, H4), 3.30 (dd, J = 14.3 and 5.3 Hz, 1H, 
CHHPh), 3.15 (dd, J = 14.3 and 9.3 Hz, 1H, CHHPh), 2.37 (ddd, J = 10.6, 5.6 and 1.5 Hz, 1H, H6eq), 2.27 (d, J 
= 10.6 Hz, 1H, H6ax), 0.92 (s, 9H,C(CH3)3), 0.91 (s, 9H,C(CH3)3), 0.18 (s, 3H, CH3), 0.16 (s, 6H, 2xCH3) and 
0.09 (s, 3H, CH3) ppm. 
13
C NMR (63 MHz, CDCl3) : 175.1 (C), 138.5 (C), 137.6 (C), 133.4 (CH), 129.1 
(2×CH), 128.6 (2×CH), 127.0 (CH), 75.7 (CH), 75.1 (C), 66.1 (CH), 57.9 (CH), 40.8 (CH2), 37.4 (CH2), 25.8 
(C(CH3)3), 25.7 (C(CH3)3), 18.2 (C(CH3)3), 18.0 (C(CH3)3), 3.0 (2×CH3), 4.5 (CH3) and 4.6 (CH3) ppm. IR 
(film): 1805 (CO) cm
-1
. MS (ESI) m/z (%) 545 (MNa
+





(1R,4R,5R)-1,4-Dihydroxy-3-[(1R)-1-chloro-2-phenyl]ethylcyclohex-2-en-1,5-carbolactone (26). A stirred 
solution of the silylether 25 (32 mg, 0.06 mmol) in dry THF (1.0 mL), under argon at 0 ºC, was treated with 
tetrabutylammonium fluoride (0.15 mL, 0.05 mmol, ca. 1.0 M in THF). The mixture was stirred for 15 min, 
saturated NH4Cl was added and the organic layer was extracted with diethyl ether (×3). The combined organic 
extracts were dried (anh. Na2SO4), filtered and concentrated under reduced pressure. The crude product was 
purified by flash chromatography on silica gel, eluting with (1:1:2) diethyl ether/acetone/hexanes, to give diol 
26 (14 mg, 79%) as a white foam. 20][ D = 6.9 (c 1.0, CHCl3). 
1
H NMR (300 MHz, CDCl3) : 7.367.28 (m, 
4H, 4×ArH), 7.18 (m, 1H, ArH), 6.08 (s, 1H, H2), 4.75 (m, 1H, CHCl), 4.70 (m, 1H, H5), 4.57 (d, J = 3.3 Hz, 
1H, H4), 3.29 (dd, J = 14.0 and 6.4 Hz, 1H, CHHPh), 3.20 (dd, J = 14.0 and 8.3 Hz, 1H, CHHPh), 2.49 (d, J = 
11.2 Hz, 1H, H6ax) and 2.38 (ddd, J = 11.2, 5.8 and 1.8 Hz, 1H, H6eq) ppm. 
13
C NMR (63 MHz, CD3OD) : 
178.1 (C), 141.0 (C), 139.2 (C), 133.4 (CH), 130.3 (2×CH), 129.4 (2×CH), 127.8 (CH), 77.7 (CH), 74.2 (C), 
66.3 (CH), 60.3 (CH), 42.3 (CH2) and 37.5 (CH2) ppm. IR (film): 3422 (OH) and 1782 (CO) cm
-1
. MS (ESI) 
m/z (%) 317 (MNa
+
). HRMS calcd for C15H15O4ClNa (MNa
+
): 317.0551; found, 317.0575.  
(1R,4R,5R)-1,4,5-Trihydroxy-3-[(1R)-1-chloro-2-phenyl]ethylcyclohex-2-en-1-carboxylic acid (10). A 
solution of carbolactone 26 (14 mg, 0.05 mmol) in THF (3.0 mL) at 0 ºC was treated with aqueous lithium 
hydroxide (0.06 mL, 0.06 mmol, 1 M) and the mixture was stirred for 2 h. Water was added and the THF was 
removed under reduced pressure. The resulting aqueous solution was washed with diethyl ether (×3) and the 
aqueous extract was treated with Amberlite IR-120 (H
+
) until pH 6. The resin was filtered off and washed with 
Milli-Q water. The filtrate and the washings were lyophilized to give acid 10 (2.9 mg, 23%) as a white solid. 
20][ D = 1.7 (c 1.0, MeOH). 
1
H NMR (500 MHz, D2O)  7.40 (m, 2H, 2×ArH), 7.34 (m, 3H, 3×ArH), 5.79 (s, 
1H, H2), 4.59 (dd, J = 9.1 and 4.4 Hz, 1H, CHCl), 4.27 (d, J = 7.4 Hz,1H, H4), 3.97 (m, 1H, H5), 3.13 (dd, J = 
14.0 and 4.4 Hz, 1H, CHHPh), 2.90 (dd, J = 14.0 and 9.1 Hz, 1H, CHHPh), and 2.11 (m, 2H, CH2-6) ppm. 
13
C 
NMR (63 MHz, D2O)  162.0 (C), 145.1 (C), 139.3 (C), 130.0 (2×CH), 129.2 (2×CH), 127.2 (CH), 125.1 




. MS (ESI) m/z (%) 311 (MH). HRMS calcd for C15H17O5Cl (MH): 311.1085; found, 
311.1087. 
(1R,4R,5R)-1,4-Di(tert-butyldimethylsilyloxy)-3-[(1S)-1-chloro-2-phenyl]ethylcyclohex-2-en-1,5-
carbolactone (27). A stirred solution of the alcohol 22 (143 mg, 0.29 mmol) in dry THF (10 mL), at room 
temperature and under argon, was treated with N-chlorosuccinimide (77 mg, 0.58 mmol) and 
triphenylphosphine (114 mg, 0.44 mmol). The reaction mixture was stirred for 1 h and the solvent was removed 
under reduced pressure. The crude product was purified by flash chromatography on silica gel, eluting with 
diethyl ether/hexanes (5:95), to give chloride 27 (66.5 mg, 44%) as a white foam. 20][ D = 13.15 (c 1.0, CHCl3). 
1
H NMR (300 MHz, CDCl3) : 7.377.24 (m, 4H, 4×ArH), 7.13 (dd, J = 6.5 and 1.6 Hz,1H, ArH), 6.00 (s, 1H, 
H2), 4.564.49 (m, 1H, CHCl), 4.43 (m, 1H, H5), 4.00 (d, J = 3.3 Hz, 1H, H4), 3.20 (m, 2H, CH2Ph), 2.30 (m, 
2H, CH2-6), 0.94 (s, 9H,C(CH3)3), 0.90 (s, 9H,C(CH3)3), 0.20 (s, 3H, CH3), 0.14 (s, 3H, CH3), 0.13 (s, 3H, CH3) 
and 0.10 (s, 3H, CH3) ppm. 
13
C NMR (63 MHz, CDCl3) : 175.2 (C), 137.9 (C), 136.8 (C), 135.3 (CH), 129.8 
(2×CH), 127.3 (2×CH), 127.0 (CH), 75.7 (CH), 74.8 (C), 67.2 (CH), 61.0 (CH), 45.5 (CH2), 37.0 (CH2), 25.9 
(C(CH3)3), 25.7 (C(CH3)3), 18.1 (C(CH3)3), 18.1 (C(CH3)3), 3.0 (2×CH3), 4.1 (CH3) and 4.4 (CH3) ppm. IR 
(film): 1802 (CO) cm
-1
. MS (ESI) m/z (%) 545 (MNa
+




(1R,4R,5R)-1,4-Dihydroxy-3-[(1S)-1-chloro-2-phenyl]ethylcyclohex-2-en-1,5-carbolactone (28). A stirred 
solution of the silylether 27 (66.5 mg, 0.13 mmol) in dry THF (3.0 mL), under argon at 0 ºC, was treated with 
tetrabutylammonium fluoride (0.3 mL, 0.3 mmol, ca. 1.0 M in THF). The mixture was stirred for 15 min, 
saturated NH4Cl was added and the organic layer was extracted with diethyl ether (×3). The combined organic 
extracts were dried (anh. Na2SO4), filtered and concentrated under reduced pressure. The crude product was 
purified by flash chromatography on silica gel, eluting with (1:1:2) diethyl ether/acetone/hexanes, to give diol 
28 (30 mg, 81%) as a white foam. 20][ D = 3.2 (c 1.0, MeOH). 
1
H NMR (250 MHz, CD3OD)  7.307.15 (m, 
5H, 5xArH), 6.05 (s, 1H, H2), 4.79 (t, J = 6.8 Hz, 1H, CHCl), 4.57 (m, 1H, H5), 4.10 (d, J = 3.3 Hz, 1H, H4), 




C NMR (63 MHz, CD3OD) : 178.2 (C), 140.2 (C), 138.4 (C), 134.7 (CH), 130.8 (2×CH), 129.3 
(2×CH), 127.8 (CH), 77.8 (CH), 74.1 (C), 66.6 (CH), 62.9 (CH), 45.6 (CH2) and 37.2 (CH2) ppm. IR (film): 
3409 (OH) and 1777 (CO) cm
-1
. MS (ESI) m/z (%) 317 (MNa
+
). HRMS calcd for C15H15O4ClNa (MNa
+
): 
317.0551; found, 317.0543. 
(1R,4R,5R)-1,4,5-Trihydroxy-3-[(1S)-1-chloro-2-phenyl]ethylcyclohex-2-en-1-carboxylic acid (9). A 
solution of carbolactone 28 (28 mg, 0.08 mmol) in THF (3.0 mL) at 0 ºC was treated with aqueous lithium 
hydroxide (0.10 mL, 0.10 mmol, 1 M) and the mixture was stirred for 2 h. Water was added and the THF was 
removed under reduced pressure. The resulting aqueous solution was washed with diethyl ether (×3) and the 
aqueous extract was treated with Amberlite IR-120 (H
+
) until pH 6. The resin was filtered off and washed with 
Milli-Q water. The filtrate and the washings were lyophilized to give acid 9 (3.0 mg, 11%) as a white solid. 
20][ D = 5.8 (c 1.0, MeOH). 
1
H NMR (300 MHz, D2O)  7.417.36 (m, 5H, 5×ArH), 5.79 (s, 1H, H2), 4.59 
(dd, J = 8.3 and 4.2 Hz, 1H, CHCl), 4.28 (d, J = 7.3 Hz, 1H, H4), 3.97 (q, J = 7.3 Hz, 1H, H5), 3.13 (dd, J = 
13.6 and 4.2 Hz, 1H, CHHPh), 2.90 (dd, J = 13.6 and 8.3 Hz, 1H, CHHPh) and 2.12 (d, J = 7.3 Hz, 2H, CH2-6) 
ppm. 
13
C NMR (63 MHz, D2O)  163.4 (C), 145.1 (C), 139.3 (C), 130.0 (2×CH), 129.2 (2×CH), 127.2 (CH), 
125.1 (CH), 73.5 (C), 72.9 (CH), 72.8 (CH), 69.9 (CH), 41.9 (CH2), and 38.8 (CH2) ppm. IR (film): 3417 (OH) 
and 1640 (CO) cm
-1
. MS (ESI) m/z (%) 311 (MH). HRMS calcd for C15H17O5Cl (MH): 311.1085; found, 
311.1052. 
Dehydroquinase assays. Both enzymes were purified as described previously.
35,36 
Concentrated solutions of 
Hp-DHQ2 (6.4 mg mL
–1
) or Mt-DHQ2 (2.4 mg mL
–1
) were stored in potassium phosphate buffer (50 mM, pH 
7.2), DTT (1 mM) and NaCl (150 mM). When required for assays, aliquots of the enzyme stock solutions were 
diluted in water and buffer and stored on ice.
 
Dehydroquinase was assayed in the forward direction by 
monitoring the increase in absorbance at 234 nm in the UV spectrum due to the absorbance of the enone-




 12 000). Standard assay conditions were 
pH 7.0 at 25 ºC in Tris.HCl (50 mM) for Hp-DHQ2 and Tris.HOAc (50 mM) for Mt-DHQ2. Each assay was 
initiated by the addition of the substrate. Solutions of 3-dehydroquinic acid (1) were calibrated by equilibration 
 28 
with DHQ2 and measurement of the change in the UV absorbance at 234 nm due to the formation of the enone-
carboxylate chromophore of 3-dehydroshikimic acid (2). The Ki values of acids 510 against DHQ2 were 
obtained from Dixon plots (1/v vs [I]) of assay data. The initial rates at fixed enzyme and substrate 
concentrations (0.25–1.4 Km) were measured in the absence and in the presence of various inhibitor 
concentrations.
 
Crystallization of Mt-DHQ2/58 binary complexes. Apo-Mt-DHQ2 crystals
37 
were soaked in 10 mM 
solutions of inhibitors 58 in the crystallization mixture [32% (v/v) 2-methyl-2,4-pentanediol, 0.3 M 
ammonium sulfate and 0.1 M 4-(2-hydroxyethyl)-piperazine-1-ethanesulfonic acid sodium salt (HEPES sodium 
salt) pH 7.5] for 6 h (inhibitors 5, 7 and 8) and 20 h (inhibitor 6). 
Structure Determination of Binary Complexes. Crystals were harvested in reservoir solution supplemented 
with 20% (v/v) glycerol, mounted into cryoloops, and flash frozen by rapid immersion in liquid nitrogen. X-ray 
diffraction data for the Mt-DHQ2/5 complex and Mt-DHQ2/78 complexes were collected on beamlines ID23-
2 and ID29 (ESRF, Grenoble, France), respectively, from crystals maintained at 100 K. Data for the Mt-
DHQ2/6 complex were collected on beamline BL13-Xaloc (Alba Synchrotron, Barcelona, Spain) from crystals 
maintained at 100 K. The data were processed, scaled, corrected for absorption effects and the crystal unit-cell 




 and other programs from the CCP4 
software suite.
40
 The structures of Mt-DHQ2/58 binary complexes were solved by molecular replacement 
using the program MOLREP
41
 with a search model generated from PDB entry 1H0S.
28
 
The structures and geometrical restraints of inhibitors were generated with the PRODRG2 server
42
 and were 
manually placed during the model building, which was performed with COOT.
43
 Reflections for calculating 
Rfree
44
 were selected randomly and refinement of the models was performed with REFMAC
45
 and final 
structure validation was performed with MOLPROBITY.
46 
The data collection, refinement and model statistics 
are summarized in Table S1 of the Supporting Information. Figures depicting structures were prepared using 
PYMOL.
47  
Molecular dynamics simulations. Ligand minimization. Ligand geometries were optimized using a restricted 
 29 
Hartree–Fock (RHF) method and a 6–31G(d,p) basis set, as implemented in the ab initio program Gaussian 
09.
48
 The charge distribution for each ligand studied was obtained by fitting the quantum mechanically 
calculated (B3LYP/cc-pVTZ and IEF-PCM as solvation model) molecular electrostatic potential (MEP) of the 
geometry-optimized molecule to a point charge model, as implemented in the assisted model building with 
energy refinement (AMBER)
49
 suite of programs. The missing bonded and non-bonded parameters were 
assigned, by analogy or through interpolation from those already present in the AMBER database (GAFF).
50 
Generation and minimization of the DHQ2-ligand complexes. For Mt-DHQ2/5–8 binary complexes, simulations 
were carried out using the enzyme geometries found in their respective crystal structures (PDB entries 4CIV, 
4CIW, 4CIX and 4CIY, respectively). For Mt-DHQ2/9–10 binary complexes, the enzyme geometries found in 
the crystal structures of Mt-DHQ2 in complex with ligands 7 (PDB entry 4CIX) and 8 (PDB entry 4CIY) were 
used after manual replacement of ligands 7–8 by 9–10, respectively. Given that the minimum catalytic unit of 
DHQ2 was experimentally determined to be a trimer,
30
 the latter was used for modelling. For Mt-DHQ2/5 
binary complex, unsolved residues were modelled using the web-based ModLoop server.
32
 For Mt-DHQ2/7–8 
binary complexes, the missing residues were modelled as PDB entry 2XB8
15
. Hydrogens were added to the 
protein using the web-based PROPKA3.1 server,
51
 which assigned protonation states to all titratable residues at 
the chosen pH of 7.0. However, δ and/or ε protonation was manually corrected for His102 (dual) of the active 
site due to mechanistic considerations and on the basis of results from preliminary MD simulations. Molecular 
mechanics parameters from the ff12SB and GAFF force fields, respectively, were assigned to the protein and 
the ligands using the LEaP module of AMBER 12.
52 
All terminal hydrogens were first minimized in vacuum 
(2000 steps, half of them steepest descent, the other half conjugate gradient). Energy minimization was carried 
out in two stages using the implicit solvent GB model; firstly protein side chains (2000 steps, idem) and 
secondly the entire complex (1000 steps, idem). Thereafter, each molecular system was immersed in a truncated 
octahedron containing TIP3P
53




 to achieve electroneutrality. 
Simulations. MD simulations were performed using the AMBER 11 suite of programs and Amber ff12SB force 
field. Periodic boundary conditions were applied and electrostatic interactions were treated using the smooth 
particle mesh Ewald method (PME)
55
 with a grid spacing of 1 Å. The cutoff distance for the non-bonded 
 30 
interactions was 9 Å. The SHAKE algorithm
56
 was applied to all bonds containing hydrogen, using a tolerance 
of 10
–5
 Å and an integration step of 2.0 fs. Minimization was carried out in three steps, starting with the 
octahedron water hydrogens, followed by solvent molecules and sodium counterions and finally the entire 









 (10 steps) and the 
resulting systems were allowed to equilibrate further. MD simulations were carried out for 10 ns. System 




Extra figures for the reported crystal structures of Mt-DHQ2/58 binary complexes, amino acid sequence 





C NMR and DEPT spectra and Dixon plots for compounds 510 are also enclosed. This material is 
available free of charge via the Internet at http://pubs.acs.org. 
Accession Codes 
Coordinates and structure factors are available from the Protein Data Bank with accession codes 4CIV, 4CIW, 
4CIX and 4CIY for Mt-DHQ2/5-8 binary complexes, respectively. 
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Scheme 1. Reaction Mechanism for the Enzymatic Conversion of 3-Dehydroquinic Acid (1) to 3-





 The reaction proceeds via enolate intermediate 3. Relevant residues are indicated. For the Hp-DHQ2 enzyme, 
the generation of the catalytic tyrosinate takes place with the assistance of a water molecule (not shown), while 





Figure 1. View of the Mt-DHQ2 Michaelis complex (A) and enolate intermediate 3 geometries (B) obtained by 
MD and QM/MM studies. Note how Asp88* from a neighboring enzyme subunit is responsible for the 
generation of the catalytic form of the essential tyrosine (tyrosinate) and that the enolate intermediate 3 is 
stabilized by the guanidinium group of Arg19 and hydrogen bonding with WAT1 and the neutral Asp88*. 
Relevant residues and water molecules are indicated and labeled. Hydrogen bonds (red) and key distances 





Figure 2. Selected examples of 3-methoxyaryl derivatives 4 that are DHQ2 competitive inhibitors and new 
target compounds 510. A selected view of the crystal structure of the Mt-DHQ2/4c binary complex (PDB: 
2Y71, 1.5 Å) is shown along with the Ki values of 4 against Mt-DHQ2. 
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Reagents and conditions: (a) ref. 20. (b) NaOAc, DMF, RT. (c) TFA/H2O (20:1), 0 ºC. (d) 1. LiOH (aq.), THF, 
RT. 2. Amberlite IR-120 (H
+
), RT. (e) ref. 21. (f) vinyl boronic acid pinacol ester, Pd(PPh3)4, K2CO3 (aq), 
dioxane, Δ. (g) 1. BH3-THF, 0 ºC; 2. NaBO3 (aq). (h) TBAF, THF, RT.  
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Reagents and conditions: (a) CO, B-benzyl-9-BBN, Pd(dppf)Cl2 (cat), K3PO4 (aq.), THF, 55 ºC. (b) TBAF, 
THF, RT. (c) NaBH(OAc)3, CeCl3, MeOH, THF, 0 ºC. (d) 1. LiOH (aq.), THF, RT. 2. Amberlite IR-120 (H
+
), 




Table 1. Ki (µM) values forcompounds 510 against Hp- and Mt-DHQ2 enzymes 





1 5  
282  8 11.2  0.2 
2 6  
188  4 15.0  0.5 
3 7 
 
37.0  0.2 34.0  0.4 
4 8 
 
33.0  0.3 27.0  0.5 
5 9 
 
40.5  4.6 14.5  0.2 
6 10 
 
10.5  0.2 0.48  0.02 
a
Assay conditions: pH 7.0, 25 ºC, 50 mM Tris.HCl; Km (1) = 444 µM;. 
b
Assay 






   
   
   
Figure 3. Binding interactions of inhibitors 5 (yellow), 6 (pink), 7 (green) and 8 (orange) in the binary 
complexes Mt-DHQ2/5 (a, PDB entry 4CIV), Mt-DHQ2/6 (b, PDB entry 4CIW), Mt-DHQ2/7 (c, PDB entry 
4CIX) and Mt-DHQ2/8 (d, PDB entry 4CIY). Comparison of the binary complexes Mt-DHQ2/5 (yellow) vs Mt-
DHQ2/6 (pink) and Mt-DHQ2/8 (orange) vs Mt-DHQ2/4c (PDB entry 2Y71, cyan) are also shown in e) and f), 
 45 
respectively. A maximum-likelihood weighted 2Fo – Fc map contoured at 1σ is shown up to 1.6 Å around the 
WAT1 molecule (red). For better comparison, water molecules in PDB entry 2Y71 are shown in yellow. 
Hydrogen-bonding interactions and distance differences between WAT2004 and WAT2001 are shown as red 
and blue dashes, respectively. Relevant residues are shown and labeled. For a)–d), the Asp88* residue from a 
symmetry-related neighboring enzyme subunit is shown in cyan.   
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 Mt-DHQ2/5 Mt-DHQ2/6 Mt-DHQ2/7 Mt-DHQ2/8 
space group F23 F23 F23 F23 
cell parameters (a, b, c), Å 126.18 126.38 126.36 126.21 
wavelength (Å) 0.87260 1.00614 0.97908 0.97908 
detector MarMOSAIC 
225 












resolution range (Å) 38.00 – 2.90 
(3.06 – 2.90) 
38.11 – 2.20 
(2.32 – 2.20) 
44.67 – 2.90 
(3.06 – 2.90) 
44.62 – 2.10 
(2.21 – 2.10) 
Wilson B (Å
2
) 37.2 17.7 25.6 25.6 
multiplicity 5.7 (2.2) 4.3 (2.6) 4.8 (5.1) 5.7 (5.9) 
completeness 0.818 (0.710) 0.992 (0.954) 0.993 (1.000) 0.999 (1.000) 




resolution range (Å) 36.45 – 2.90 
(3.06 – 2.90) 
38.13 – 2.20 
(2.32 – 2.20) 
38.13 – 2.90 
(3.06 – 2.90) 
38.08 – 2.10 
(2.21 – 2.10) 
reflections used in refinement
c
 2958 (355) 8152 (1122) 3589 (504) 9359 (1359) 
reflections used for Rfree 141 (26) 409 (72) 168 (31) 472 (70) 
R-factor
e
 0.212 (0.299) 0.142 (0.181) 0.152 (0.222) 0.145 (0.166) 
Rfree
f
 0.279 (0.405) 0.192 (0.296) 0.189 (0.269) 0.197 (0.224) 




















 (%) 95.5/99.3 99.3/100.0 96.1/100.0 96.2/100.0 
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No sigma cut-off or other restrictions were used for inclusion of reflections. 
c
Values in 















According to the program MOLPROBITY.
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 The percentages 





   
   
   
Figure 4. Comparison of the binding mode of the inhibitors 7, 8, 9 and 10 in the binary complexes Mt-DHQ2/7 
(A,B), Mt-DHQ2/8 (E), Mt-DHQ2/9 (C,D) and Mt-DHQ2/10 (F) after minimization and prior simulation (gray) 
and after 10 ns of dynamic simulation (yellow). For Mt-DHQ2/7 and Mt-DHQ2/9 binary complexes, MD 
simulations were carried out with (A,C) and without WAT1 (B,D), respectively. Note how, for the Mt-DHQ2/9 
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binary complex, WAT1 is expelled from the WAT1 binding pocket during simulation while remains in place 
for Mt-DHQ2/10. Relevant side chain residues are shown and labeled. Relevant hydrogen-bonding (red), 
halogen-bonding (blue) and CH…Cl interactions (black) are shown. For Mt-DHQ2/7 binary complex (A), 
distance differences between WAT1 after minimization and prior simulation and after 10 ns of dynamic 
simulation are shown as dashed lines (magenta).   
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